Kiniksa signs manufacturing agreement with Samsung Biologics for ARCALYST

Kiniksa Pharmaceuticals International, plc

Wholly-owned subsidiary entered MSA and PSA with Samsung Biologics for ARCALYST (rilonacept) drug substance.
Kiniksa committed to purchase PPQ and pre-approval inspection batches; additional batches required in 2027-2031.
PSA continues until later of Dec 31, 2031 or service completion; MSA initial 10-year term with 2-year auto-renewals.
Agreement includes customary indemnification, IP protection, limitation of liability, and confidentiality provisions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.